United States Drug Patent 7,226,614: Claim Scope, Expiration, Litigation Risk, and Patent Landscape

U.S. Patent No. 7,226,614 protects a segmented tablet combining cetirizine and pseudoephedrine, principally where the two active ingredients occupy separate tablet segments with an interfacial surface area below 180 mm². Claim 1 also requires less than 5% by weight of an alkalinizing agent and substantial freedom from cetirizine-pseudoephedrine reaction impurities. Claim 2 instead requires pharmacokinetic performance substantially equivalent to separate dosage forms.

The patent was assigned to UCB Pharma-related interests and has reached the end of its ordinary patent term. It no longer presents a live U.S. patent barrier to generic cetirizine-pseudoephedrine products. Its historical importance was concentrated in the formulation and manufacturing design of Zyrtec-D-type products, not in the active ingredients themselves.

What does U.S. Patent 7,226,614 cover?

The patent covers a method of treatment using a physically segmented tablet containing cetirizine and pseudoephedrine in separate segments. The claims do not broadly cover every combination of the two ingredients.

The central technical limitation is separation of the active ingredients within the tablet. One segment must contain predominantly cetirizine, and a second segment must contain predominantly pseudoephedrine. The segments must be formed to limit chemical interaction between the ingredients.

Claim element	Claim 1	Claim 2
Treatment of rhinitis, congestion, allergy, cold or flu symptoms	Yes	Yes
Tablet dosage form	Yes	Yes
At least two distinct segments	Yes	Yes
Predominantly cetirizine segment	Yes	Yes
Predominantly pseudoephedrine segment	Yes	Yes
Interfacial surface area below 180 mm²	Yes	Yes
Substantially free of reaction impurities	Yes	No express limitation
Less than 5% alkalinizing agent by tablet weight	Yes	No
Pharmacokinetic equivalence to separate active-ingredient dosage forms	No express limitation	Yes

The claims are method claims. Literal infringement therefore requires use or sale of a product with the claimed characteristics for the claimed therapeutic purposes, rather than merely possession of cetirizine or pseudoephedrine.

How does the 180 mm² interfacial-area limitation affect infringement?

The 180 mm² limitation is a quantitative structural requirement. It is likely the most important claim boundary for product assessment.

A product can fall outside the literal scope if the interface between the cetirizine and pseudoephedrine segments is 180 mm² or greater. The relevant interface is the contact surface between the two active-ingredient-containing segments, not necessarily the total external surface area of the tablet.

Potentially relevant designs include:

Bilayer tablets with a single planar interface.
Core-and-coat tablets in which one active ingredient surrounds or encloses another.
Press-coated tablets.
Tablets with separate longitudinal segments.
Multilayer tablets containing inert barriers.
Multiparticulate capsules, if they are not tablets.
Physically separated tablets packaged together rather than a single segmented tablet.

A bilayer tablet may have a relatively large interface depending on tablet geometry. A smaller central core, segmented geometry, or inert barrier can reduce direct contact. The patent specification and prosecution history would be relevant to determining how the measurement is made, particularly for curved, irregular, or multilayer tablets.

A design that uses an inert barrier may reduce direct cetirizine-pseudoephedrine contact, but it does not automatically avoid infringement. The analysis would depend on whether the two active segments still have an interface with one another and whether the product satisfies the remaining limitations.

What is the difference between claim 1 and claim 2?

Claim 1 is directed to chemical compatibility and excipient control. Claim 2 is directed to pharmacokinetic performance.

Claim 1 requires the tablet to be substantially free of impurities formed by reaction between cetirizine and pseudoephedrine. It also limits alkalinizing agents to less than 5% by weight. This creates a formulation-centered claim that may be tested through stability studies, impurity analysis, composition records, and manufacturing documentation.

Claim 2 does not include the express alkalinizing-agent limitation. It requires that the cetirizine and pseudoephedrine pharmacokinetic profiles be substantially the same as those achieved when each active ingredient is administered alone in the same amount.

The terms “substantially free,” “predominantly,” and “substantially the same” create potential claim-construction disputes. Their meaning would depend on the specification, examples, prosecution history, and technical evidence. Claim 2 may be harder to evaluate from a finished-product label alone because pharmacokinetic equivalence may require comparative clinical or bioavailability data.

What formulations are protected by U.S. Patent 7,226,614?

The patent is directed to segmented tablets, not all cetirizine-pseudoephedrine dosage forms.

Potentially covered formulations include:

A bilayer tablet with cetirizine in one layer and pseudoephedrine in the other.
A tablet with a cetirizine core and a pseudoephedrine outer segment.
A tablet with a pseudoephedrine core and a cetirizine outer segment.
A multilayer tablet in which the active segments remain separated and meet the interface limitation.
An extended-release pseudoephedrine segment combined with an immediate-release cetirizine segment, if the physical and pharmacokinetic limitations are satisfied.

The patent does not, on the claim language provided, directly cover:

A conventional single-phase tablet in which both ingredients are uniformly mixed.
A capsule containing separate beads or granules, unless interpreted under a broader equivalent theory.
Two separate tablets administered together.
A formulation containing cetirizine alone.
A formulation containing pseudoephedrine alone.
A product whose segment interface is at least 180 mm².
A product that does not achieve the claimed pharmacokinetic relationship in the case of claim 2.

The phrase “predominantly” may allow excipients and other materials in each active segment, but a segment dominated by a different active pharmaceutical ingredient would create a stronger noninfringement position.

When did U.S. Patent 7,226,614 expire?

The patent’s ordinary 20-year term ran from its earliest effective nonprovisional filing date, subject to any patent-term adjustment or terminal disclaimer reflected in the official patent record. The patent was issued on June 5, 2007, and its enforceable term ended in 2022 under the applicable U.S. patent-term framework. The U.S. Patent and Trademark Office patent record is controlling for the exact expiration calculation. (U.S. Patent and Trademark Office, 2007)

Because the patent has expired, it cannot support a new U.S. infringement action against a current generic entrant. Historical litigation, prosecution history, and technical disclosures remain relevant for prior-art analysis and freedom-to-operate diligence, but the claims no longer provide prospective exclusivity.

Exclusivity timeline

Event	Timing
Priority and patent-family development	Early 2000s
U.S. patent application	Early 2000s
Patent issued	June 5, 2007
Expected ordinary patent-term endpoint	2022
Current status	Expired
Current U.S. blocking effect	None from this patent

The patent term should not be confused with FDA marketing exclusivity. Regulatory exclusivity and patent exclusivity are separate rights. FDA approval of a cetirizine-pseudoephedrine product did not extend the patent beyond its statutory term.

What was the Orange Book status of the patent?

The Orange Book status must be assessed against the specific reference-listed drug and NDA record. Patent listings can change over time, and an Orange Book listing does not itself establish validity or infringement.

Historically, UCB-related patents covering cetirizine-pseudoephedrine combination products were associated with the Zyrtec-D product family and its FDA regulatory filings. The principal commercial product used cetirizine hydrochloride and extended-release pseudoephedrine hydrochloride, generally in a 5 mg/120 mg tablet configuration. FDA labeling identifies the product as an extended-release combination for allergic rhinitis and nasal congestion. (U.S. Food and Drug Administration, n.d.-a)

As of the patent’s expiration, 7,226,614 should not be treated as a live Orange Book barrier. Any current Orange Book analysis should separately review:

Whether the patent remains listed against the relevant NDA.
Whether the listing has been removed after expiration.
Whether other patents cover the reference product.
Whether any listed patent concerns formulation, method of use, or drug substance.
Whether the ANDA applicant made a Paragraph IV certification or a certification based on expiration.

Were there Paragraph IV challenges to this patent?

A Paragraph IV certification may challenge the validity, enforceability, or infringement of an Orange Book-listed patent. The certification can trigger patent litigation under the Hatch-Waxman Act.

For 7,226,614, the practical importance of any Paragraph IV challenge was limited to the period before patent expiration. After expiration, an applicant no longer needs to establish an early launch position against this patent because the patent cannot block commercial entry.

The most relevant historical issues for a Paragraph IV analysis would have been:

Whether a generic tablet had two distinct segments.
Whether the interfacial area was below 180 mm².
Whether the product contained less than 5% alkalinizing agent.
Whether the product generated cetirizine-pseudoephedrine reaction impurities.
Whether pharmacokinetic profiles matched the separate-active-ingredient reference products.
Whether the patent claims were obvious over earlier combination-tablet and bilayer-tablet disclosures.

A Paragraph IV certification against an expired patent has no continuing exclusionary effect. FDA ANDA records and court dockets should be used to identify the exact applicants and certifications associated with the patent. (U.S. Food and Drug Administration, n.d.-b)

What patent litigation affected U.S. Patent 7,226,614?

The patent sits within the broader UCB cetirizine-pseudoephedrine patent family and was relevant to generic challenges involving Zyrtec-D-type products. Patent disputes in this area typically involved related patents covering the combination, tablet architecture, release characteristics, and chemical stability rather than only one patent in isolation.

A complete litigation assessment requires separating:

Cases naming U.S. Patent 7,226,614 directly.
Cases involving related UCB patents.
ANDA litigation under 35 U.S.C. §271(e)(2).
Declaratory-judgment actions.
Settlements that permitted launch before expiration.
Cases dismissed after patent expiration.
Cases involving different strengths or dosage forms.

The claims provided do not establish whether a particular defendant infringed. Product-specific evidence would be required. Public patent litigation records should be reviewed through PACER, CourtListener, and USPTO assignment and litigation data. The patent’s expiration eliminates current injunctive risk, but historical settlements may explain why generic products entered before 2022.

How strong was the patent estate for cetirizine-pseudoephedrine products?

The patent estate was stronger as a portfolio than as a single claim. UCB and related rights holders could potentially combine:

Combination-product patents.
Segmented-tablet patents.
Extended-release pseudoephedrine claims.
Chemical-stability claims.
Method-of-use claims.
Manufacturing and tablet-compression claims.
Regulatory exclusivity and brand-label rights.

U.S. Patent 7,226,614 had several strengths:

It targeted a specific compatibility problem between cetirizine and pseudoephedrine.
It included a measurable interface limitation.
It tied the formulation to clinical treatment uses.
Claim 2 captured pharmacokinetic performance rather than only composition.

Its weaknesses included:

Dependence on functional and qualitative terms.
Potential measurement disputes over the interfacial area.
Design-around potential through capsules, separate tablets, inert barriers, or different tablet geometry.
Obviousness risk from prior-art multilayer and bilayer dosage forms.
The requirement in claim 2 to prove pharmacokinetic equivalence.
Expiration in 2022.

The patent therefore had meaningful historical value for controlling a specific tablet architecture, but it was not a broad monopoly over the active ingredients or the therapeutic combination.

What manufacturing and intellectual-property barriers remain?

The expired patent does not remove technical barriers associated with product development.

A current manufacturer still must address:

Compatibility between cetirizine and pseudoephedrine.
Formation of degradation or reaction impurities.
Extended-release control for pseudoephedrine.
Dose uniformity across tablet segments.
Mechanical integrity during compression, coating, packaging, and transport.
Dissolution performance for both active ingredients.
Stability under humidity and temperature stress.
FDA requirements for an ANDA demonstrating pharmaceutical equivalence and bioequivalence.
Federal and state controls applicable to pseudoephedrine sales.

The expired patent’s examples and formulation teachings can assist development, but they may also create prior-art constraints against later patent applications claiming substantially the same tablet architecture.

How does the patent compare with alternative product designs?

Product design	Likely relationship to 7,226,614
Bilayer tablet with small cetirizine-pseudoephedrine interface	Historically high relevance
Bilayer tablet with interface of 180 mm² or more	Potential literal noninfringement
Uniform blend tablet	Generally outside the segmented-tablet limitations
Capsule with separate pellets	Generally outside the tablet limitation
Two separate tablets taken together	Generally outside the single-tablet requirement
Tablet with inert barrier between active layers	Depends on construction and whether active segments interface
Cetirizine-only product	Outside the combination claims
Pseudoephedrine-only product	Outside the combination claims
Current product after patent expiration	No current infringement exposure from this patent

A product may avoid literal infringement while still requiring analysis of related patents, regulatory exclusivity, trade secrets, and other jurisdictions.

What is the geographic coverage of the patent family?

U.S. Patent 7,226,614 provides rights only in the United States. Foreign counterparts must be evaluated separately. Relevant jurisdictions for a commercial cetirizine-pseudoephedrine product would include the European Patent Convention states, Canada, Australia, Japan, and other markets where the combination was sold.

Foreign patents may differ in:

Claim scope.
Filing and priority dates.
Patent-term calculation.
Supplementary protection certificate treatment.
Validity outcomes.
Litigation history.
Regulatory linkage.
Expiration dates.

A U.S. expiration does not establish that a corresponding European or Canadian patent expired on the same date.

What generic entry risks exist today?

There is no current U.S. launch-blocking risk from U.S. Patent 7,226,614 because the patent has expired. The remaining risks are commercial and regulatory rather than based on this patent’s enforceability.

Generic entrants may still face:

ANDA approval requirements.
Bioequivalence and dissolution testing.
Product-liability exposure.
Pseudoephedrine distribution restrictions.
Brand competition from Zyrtec-D and store-brand equivalents.
Other unexpired patents, if any, associated with a particular reference-listed product.
State-level pharmacy and sales controls.
Manufacturing complexity for extended-release tablets.

The product is a small-molecule combination, so biosimilar regulation does not apply. FDA review proceeds through the generic-drug framework rather than the biosimilar pathway.

What licensing deals and commercial relationships were relevant?

Cetirizine commercialization involved UCB and major commercial partners, including Pfizer in the broader Zyrtec franchise. Commercial promotion, distribution, and marketing rights are distinct from patent ownership. A license to market Zyrtec-D would not necessarily transfer ownership of U.S. Patent 7,226,614.

For diligence, the relevant documents are:

USPTO assignment records.
FDA NDA ownership and transfer records.
SEC disclosures by UCB or Pfizer.
License and collaboration agreements.
Settlement agreements from ANDA litigation.
Product-label and manufacturing-authority records.

The patent record alone cannot establish the full scope of commercial licensing rights.

Key Takeaways

U.S. Patent 7,226,614 covers a cetirizine-pseudoephedrine segmented tablet, not the active ingredients broadly.
Both claims require a tablet with distinct cetirizine and pseudoephedrine segments.
The 180 mm² interfacial-area limitation is the principal structural boundary.
Claim 1 adds reaction-impurity and alkalinizing-agent limitations.
Claim 2 adds a pharmacokinetic-equivalence requirement.
The patent expired in 2022 and does not currently block U.S. generic entry.
Biosimilar risk is irrelevant because cetirizine and pseudoephedrine are small molecules.
Current diligence should focus on other patents, FDA requirements, manufacturing capability, pseudoephedrine controls, and historical settlements.
Foreign counterparts require separate expiration and enforcement analysis.

FAQs

Does U.S. Patent 7,226,614 cover Zyrtec-D itself?

Historically, it was relevant to Zyrtec-D-type products containing cetirizine and extended-release pseudoephedrine in a segmented tablet. It did not independently define every commercial feature of Zyrtec-D.

Can a generic manufacturer use a single-layer cetirizine-pseudoephedrine tablet?

A single-layer tablet with a uniform active-ingredient blend would generally fall outside the express “at least two distinct segments” limitation. Other patents and FDA requirements would still require review.

Is the 180 mm² interface measured from the entire tablet surface?

The claim refers to the interfacial surface area of the pseudoephedrine and cetirizine segments. The measurement ordinarily concerns the contact interface between those segments, not the tablet’s entire external surface.

Does patent expiration eliminate the need for bioequivalence testing?

No. Expiration removes the patent barrier but does not eliminate FDA requirements for pharmaceutical equivalence, bioequivalence, quality, stability, dissolution, labeling, and manufacturing controls.

Can the expired patent still affect new patent applications?

Yes. Its disclosure can operate as prior art against later patent applications claiming the same segmented cetirizine-pseudoephedrine architecture or closely related formulation concepts.

References

U.S. Food and Drug Administration. (n.d.-a). Zyrtec-D labeling and prescribing information. FDA Drugs@FDA.
U.S. Food and Drug Administration. (n.d.-b). Approved drug products with therapeutic equivalence evaluations. FDA Orange Book.
U.S. Patent and Trademark Office. (2007). U.S. Patent No. 7,226,614: Pharmaceutical composition comprising cetirizine and pseudoephedrine. U.S. Department of Commerce.
U.S. Patent and Trademark Office. (n.d.). Patent term adjustment and patent term information. U.S. Department of Commerce.
U.S. Congress. (1984). Drug Price Competition and Patent Term Restoration Act, Pub. L. No. 98-417, 98 Stat. 1585.

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
	01115807	Jun 28, 2001

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	034866	⤷ Start Trial
Austria	432068	⤷ Start Trial
Australia	2002345024	⤷ Start Trial
Bulgaria	108452	⤷ Start Trial
Bulgaria	66269	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 7,226,614

Summary for Patent: 7,226,614